Churg-Strauss syndrome associated with omalizumab
Xavier Puéchal1, Philippe Rivereau, François Vinchon
1Department of Rheumatology, Le Mans General Hospital, 194 avenue Rubillard, 72000 Le Mans, France. xpuechal@ch-lemans.fr
Abstract:
Reports have suggested that the leukotriene receptor antagonists may cause Churg-Strauss syndrome following the tapering of oral corticosteroids or even in patients not treated with corticosteroids. We report a patient not treated with long-term corticosteroids and who developed Churg-Strauss syndrome with myocarditis and central nervous system involvement following the initiation of omalizumab. Given the possible role of omalizumab in the development of this vasculitis in our patient, we recommend careful monitoring of the appearance of Churg-Strauss symptoms and rising eosinophil count in patients treated with omalizumab.
Related Concept Videos
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Hypersensitivity Reactions: Immune-Complex Reactions
Asthma III: Clinical Manifestations
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Esophageal Achalasia

